<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596592</url>
  </required_header>
  <id_info>
    <org_study_id>19-1226</org_study_id>
    <secondary_id>1K23HL151868-01</secondary_id>
    <nct_id>NCT04596592</nct_id>
  </id_info>
  <brief_title>Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth</brief_title>
  <acronym>PUBERTY</acronym>
  <official_title>Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone&#xD;
      analogue on insulin sensitivity and vascular function in transgender females compared to&#xD;
      cisgender controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial artery flow mediated dilation</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Large artery stiffness</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>Carotid artery ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular function</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>Middle cerebral artery blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 peak</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-free mass</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>DXA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Transgenderism</condition>
  <condition>Gender Dysphoria</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Transgender</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisgender</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional consent for DNA collection and storage&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Transgender and cisgender adolescents&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (transgender females):&#xD;
&#xD;
          -  Identify as a transgender female&#xD;
&#xD;
          -  Age 13-16 years at the time of enrollment&#xD;
&#xD;
          -  If on a gonadotropin releasing hormone analogue, &gt; 6 months exposure&#xD;
&#xD;
          -  Plan to start estradiol clinically in &lt; 4 months&#xD;
&#xD;
        Inclusion Criteria (cisgender males and females):&#xD;
&#xD;
          -  Males and females ages 13-16 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the&#xD;
             study procedures&#xD;
&#xD;
          -  Antipsychotic medication use&#xD;
&#xD;
          -  Type 1 or 2 diabetes (by medical history)&#xD;
&#xD;
          -  Polycystic ovarian syndrome (PCOS for cisgender females)&#xD;
&#xD;
          -  Hypertension (resting BP â‰¥ 140/90 mm/Hg)&#xD;
&#xD;
          -  Weight&gt; 400 lbs&#xD;
&#xD;
          -  On oral progesterone medications (including oral progesterone or progestin, combined&#xD;
             oral contraceptives or etonogestrel implant)&#xD;
&#xD;
          -  Pregnancy (for cisgender females)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Natalie Nokoff, MD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Nokoff, MD, MSCS</last_name>
    <phone>720-777-3607</phone>
    <email>Natalie.Nokoff@childrenscolorado.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Nokoff, MD</last_name>
      <phone>720-777-3607</phone>
      <email>natalie.nokoff@childrenscolorado.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

